A Mechanism for Cell-Cycle Regulation of MAP Kinase Signaling in a Yeast Differentiation Pathway  by Strickfaden, Shelly C. et al.
A Mechanism for Cell-Cycle Regulation
of MAP Kinase Signaling in a Yeast
Differentiation Pathway
Shelly C. Strickfaden,1 Matthew J. Winters,1 Giora Ben-Ari,2 Rachel E. Lamson,1 Mike Tyers,2,3
and Peter M. Pryciak1,*
1Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Worcester, MA 01605, USA
2Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, M5G 1X5, Canada
3Department of Medical Genetics and Microbiology, University of Toronto, Toronto, M5S 1A8, Canada
*Correspondence: peter.pryciak@umassmed.edu
DOI 10.1016/j.cell.2006.12.032SUMMARY
Yeast cells arrest in the G1 phase of the cell
cycle upon exposure to mating pheromones.
As cells commit to a new cycle, G1 CDK activity
(Cln/CDK) inhibits signaling through the mating
MAPK cascade. Here we show that the target of
this inhibition is Ste5, the MAPK cascade
scaffold protein. Cln/CDK disrupts Ste5 mem-
brane localization by phosphorylating a cluster
of sites that flank a small, basic, membrane-
binding motif in Ste5. Effective inhibition of
Ste5 signaling requires multiple phosphoryla-
tion sites and a substantial accumulation of
negative charge, which suggests that Ste5
acts as a sensor for high G1 CDK activity.
Thus, Ste5 is an integration point for both exter-
nal and internal signals. When Ste5 cannot be
phosphorylated, pheromone triggers an aber-
rant arrest of cells outside G1 either in the pres-
ence or absence of the CDK-inhibitor protein
Far1. These findings define a mechanism and
physiological benefit of restricting antiprolifera-
tive signaling to G1.
INTRODUCTION
Cellular decisions are commonly regulated by external
signals via mitogen-activated protein (MAP) kinase cas-
cades (Qi and Elion, 2005). Though widely appreciated
to stimulate cell proliferation, MAP kinase (MAPK) path-
ways can also regulate cell differentiation. Relatively little
is known about how differentiation and antiproliferative
signals may be integrated with or counteracted by the
cell-division status of individual cells. In yeast, mating
pheromones activate a MAPK cascade to trigger fusion
between two haploid gamete cells (Dohlman and Thorner,
2001). This mating reaction exhibits fundamental hall-
marks of differentiation: cells exit the cell cycle, inducea unique program of gene expression, and undergo mor-
phogenetic changes that allow them to adopt a new
fate. Mating pheromones cause cells to arrest specifically
in the G1 stage of the cell cycle prior to the G1/ S tran-
sition step known as ‘‘Start.’’ However, cells that have al-
ready passed Start become refractory to pheromone ar-
rest; this property was used to define Start as a unique
point of commitment to a new round of division (Hartwell
et al., 1974).
One contributor to the G1 specificity of pheromone ar-
rest is the mutual antagonism between cyclin-dependent
kinases (CDKs) and Far1, a CDK inhibitor (Chang and
Herskowitz, 1990). Pheromone signaling in G1 cells allows
theMAPKFus3 to phosphorylate and activate Far1 (Chang
and Herskowitz, 1992; Breitkreutz et al., 2001), which in
turn inhibits CDK activity associated with G1 cyclin (Cln)
proteins by an unresolved mechanism (Peter and Hersko-
witz, 1994; Gartner et al., 1998; Jeoung et al., 1998). Con-
versely, as cells pass Start, Cln/CDKs phosphorylate Far1
and target it for degradation (McKinney et al., 1993;
Henchoz et al., 1997). However, other mechanisms may
play an equally critical role in restricting pheromone arrest
to G1, but they are poorly understood. In particular, signal
transduction through the MAPK cascade is actively in-
hibited by G1 CDKs in a way such that pheromone-
induced transcription of mating genes (e.g., FUS1) is
minimized during periods of maximum G1 cyclin expres-
sion (Oehlen and Cross, 1994; Wassmann and Ammerer,
1997). As a result, cells are unresponsive to pheromone
during a period that runs from Start through S phase.
While G1 CDK inhibition of pheromone signaling has
been recognized for many years, the target and mecha-
nism have remained elusive. Previous studies suggested
that the inhibited step of the signaling pathway lay some-
where between the heterotrimeric G protein bg dimer
(Gbg) and the first kinase of the MAPK cascade, the
MAPKKK Ste11 (Wassmann and Ammerer, 1997; Oehlen
and Cross, 1998). Indeed, Cln2/CDK can phosphorylate
the PAK-family kinase Ste20 (Oehlen and Cross, 1998;
Wu et al., 1998), but removing CDK sites in Ste20 had
no effect on the ability of Cln/CDK to inhibit pheromoneCell 128, 519–531, February 9, 2007 ª2007 Elsevier Inc. 519
Figure 1. Cln2/CDK Antagonizes Membrane-Localized Sig-
naling Mediated by the Ste5 PM Domain
(A) This diagram shows the pheromone response pathway and the
membrane recruitment of Ste5.
(B) Methods for activating membrane-localized signaling are shown.
From left to right, they are: a factor (af) treatment or Gb overexpression
(Whiteway et al., 1990); hyperactive membrane localization of Ste5 via
an enhanced PM domain (Winters et al., 2005); membrane targeting of
Ste5 via a foreign transmembrane domain (Pryciak and Huntress,
1998); and membrane targeting of Ste11 via a prenylation/palmitoyla-
tion motif (Winters et al., 2005).
(C) Cln2/CDK inhibition correlates with dependence on the Ste5 PM
domain. Pathway-activating components were expressed from the
GAL1 promoter and were compared for their ability to induce FUS1-
lacZ transcription in ste4D strains ± PGAL1-CLN2 (n = 4).520 Cell 128, 519–531, February 9, 2007 ª2007 Elsevier Inc.signaling (Oda et al., 1999). Thus, this failed to confirm
Ste20 as a relevant target. In the interim, our understand-
ing of this signaling pathway has advanced considerably.
An important step in activation of the mating pathway
(see Figure 1A) is the plasma membrane recruitment of
the MAPK cascade scaffold protein Ste5 by the phero-
mone-activated Gbg dimer (Pryciak and Huntress, 1998;
Mahanty et al., 1999; van Drogen et al., 2001; Winters
et al., 2005). Indeed, artificial targeting of Ste5 to the
plasma membrane causes constitutive signaling (Pryciak
and Huntress, 1998). Membrane recruitment of Ste5
serves two roles: (1) it promotes activation of Ste11 by
its membrane-localized activator, Ste20 (Pryciak and
Huntress, 1998; van Drogen et al., 2000), and (2) it am-
plifies signal transmission from active Ste11 through the
remainder of the kinase cascade (Lamson et al., 2006).
Recently, we found that although Gbg is the usual trigger
for Ste5 recruitment, it is not sufficient. Instead, Ste5 also
binds directly to membranes, and cooperativity between
these two weak interactions (Ste5-Gbg and Ste5-
membrane) controls membrane recruitment (Winters
et al., 2005). The Ste5-membrane interaction requires an
N-terminal ‘‘PM’’ (plasma membrane-binding) domain,
which is a short basic-rich amphipathic a helix that binds
acidic phospholipidmembranes andwhich can also target
Ste5 to the nucleus when it is not engaged at the plasma
membrane. Gain-of-function mutations in the PM domain
cause increased membrane affinity, which allows Ste5 to
localize to the plasma membrane and activate signaling
even without Gbg (Winters et al., 2005).
In this study, we report that G1 CDK activity inhibits
pheromone signaling by inhibiting Ste5membrane recruit-
ment. The Ste5 PM domain is flanked by multiple CDK
sites that are phosphorylated by G1 CDKs in vivo and in
vitro, and the addition of multiple negatively charged
phosphates impedes binding to acidic phospholipid
membranes. Furthermore, we show that when CDK regu-
lation of Ste5 is disrupted, pheromone signaling blocks
cell-cycle progression even after cells pass Start and
even in the absence of Far1; this provides a physiological
rationale for antagonizing pheromone signaling as cells
begin a new division cycle.
(D) Ste20-independent signaling is sensitive to Cln2 inhibition. Wild-
type Ste11 (WT) or a Ste20-independent mutant (Ste11-Asp3) was
expressed in ste11D or ste11D ste20D strains ± PGAL1-CLN2. FUS1-
lacZ induction was measured after a factor treatment (n = 6).
(E) PM domain mutations that disrupt nuclear targeting (NLSm) do not
affect Cln2 inhibition. FUS1-lacZ was induced by a factor treatment in
ste5D ± PGAL1-CLN2 strains expressing Ste5-WT or Ste5-NLSm
(n = 9).
(F) Increased Ste5 membrane affinity causes increased resistance to
Cln2. Left: Ste5 variants contained PM domain mutations that increase
membrane affinity. Right: the native PM domain was replaced with
one or two copies of the PLCd PH domain. All forms were expressed
from the native STE5 promoter in ste5D strains ± PGAL1-CLN2, and
response to a factor was measured (n = 4–9).
Data in all bar graphs show the mean ± SD.
RESULTS
G1 CDKs Inhibit the Function of the Ste5 PM Domain
To identify the target of Cln/CDK inhibition we used
several new tools to dissect early steps in the mating
pathway. First, activated forms of various pathway com-
ponents (Figure 1B) were expressed from a strong,
galactose-inducible promoter (PGAL1) to bypass upstream
signaling steps. We then compared signaling with and
without overexpression of Cln2, which is the G1 cyclin
that is most potent at inhibiting pheromone response
(Oehlen and Cross, 1994). While each activation method
caused strong signaling, only those that required the
Ste5 PM domain could be inhibited by Cln2 (Figure 1C).
Especially revealing is the comparison between Ste5-
Q59L and Ste5-CTM. Both activate signaling by targeting
Ste5 to the plasma membrane, and both bypass Gbg but
still require Ste20 (Pryciak and Huntress, 1998; Winters
et al., 2005), yet they behaved oppositely with regard to
Cln2 sensitivity: Ste5-Q59L (which is targeted to themem-
brane by an enhanced PM domain; Winters et al., 2005)
was sensitive to Cln2 inhibition, whereas Ste5-CTM
(which is targeted to the membrane by a foreign trans-
membrane domain; Pryciak and Huntress, 1998) was
resistant. Furthermore, when comparing two Ste11 deriv-
atives, we found that Ste11-Cpr (which requires the Ste5
PM domain; Winters et al., 2005) remained sensitive to
Cln2 inhibition, whereas Ste11DN (which bypasses Ste5
altogether; Pryciak and Huntress, 1998) was resistant.
These results argue that G1 CDK inhibition does not act
on Gbg, Ste20, Ste11, or even the ability of Ste5 to facili-
tate signaling through theMAPK cascade. Instead, signal-
ing is inhibited only when membrane localization by the
Ste5 PM domain is required.
In addition to promoting the initial Ste20/ Ste11 step,
membrane localization of Ste5 serves a second, Ste20-
independent role in boosting signal transmission from ac-
tive Ste11 through the MAPK cascade (Lamson et al.,
2006). Because of this ‘‘amplification’’ effect, pheromone
can stimulate signaling in ste20D cells that harbor a preac-
tivated Ste11 mutant, Ste11-Asp3 (Lamson et al., 2006).
Cln2 still inhibited this Ste20-independent response
(Figure 1D), which indicates that there must be a target
other than Ste20. Notably, however, partial Cln2 resis-
tance was observed. Yet because this was true for both
the Ste20-independent signaling by Ste11-Asp3 (Fig-
ure 1D) and the Ste20-dependent signaling by Ste11-
Cpr (Figure 1C), it did not reflect the participation of
Ste20 per se. Rather, we suggest that Cln2 inhibition is
strongest when it can antagonize two successive signal-
ing steps that each rely on Ste5 membrane localization
and that it becomes incomplete when the first step is
bypassed by prelocalization or preactivation of Ste11.
Further experiments showed that Cln2/CDK inhibition of
pheromone response could be reversed by strengthening
the Ste5-membrane interaction. First, mutations in the PM
domain (Winters et al., 2005) that enhance membrane
binding (T52L, Q59L, or a T52L Q59L double mutant) re-duced Cln2 inhibition (Figure 1F, left) from 89% (wild-
type [WT]) to 34% (T52L Q59L). Second, by replacing
the native Ste5 PM domain with foreign membrane-
binding motifs (Winters et al., 2005), we found that signal-
ing remained Cln2 sensitive when we used a relatively
weak motif, the PH domain from PLCd, but that signaling
became Cln2 resistant when we used two tandem copies
of this same motif (Figure 1F, right). The PM domain can
also target Ste5 into the nucleus (Winters et al., 2005),
but Cln2 sensitivity was not changed by a PM domain
mutation (NLSm; Figure 1E) that specifically disrupts
nuclear localization (Winters et al., 2005). Collectively,
our results suggest that Cln/CDK antagonizes the ability
of the Ste5 PM domain to mediate membrane-localized
signaling.
Multiple CDK Sites Flanking the Ste5 PM Domain
Regulate Signaling
Of 15 possible CDK sites (i.e., SP or TP) within Ste5, eight
are concentrated around the PM domain (Figure 2A). This
conspicuous clustering, when coupled with results de-
scribed above, suggested that phosphorylation at one or
more of these sites might regulate Ste5 signaling. Indeed,
small deletions on either side of the Ste5 PM domain con-
ferred partial Cln2 resistance (Figure S1B). Therefore, we
replaced the Ser or Thr residues at all eight SP/TP sites
with nonphosphorylatable Ala residues. This ‘‘Ste5-8A’’
mutant remained fully capable of pheromone response
but was now completely resistant to Cln2 inhibition (Fig-
ures 2B and S1C). This phenotype was specific to the
Ste5-8A mutant, as a previously described Ste20 mutant,
Ste20-13A, which lacks 13 CDK sites (Oda et al., 1999),
conferred no Cln2 resistance in parallel tests (Figure 2B).
Furthermore, the Cln2 resistance displayed by Ste5-8A
was separable from any possible effects on Ste5-Gbg
binding because Gbg-independent signaling by PGAL1-
STE5-Q59L became resistant to Cln2 when Ste5 harbored
the 8A mutations (Figure 2C). We also examined Ste5-8A
signaling in synchronous cultures (Figure 2D). As cells pro-
gressed through the cell cycle, pheromone response was
monitored by transcriptional induction of a FUS1-lacZ
reporter and by phosphorylation of the MAPK Fus3. By
either assay, Ste5-8A largely disrupted the normal cell-
cycle periodicity of pheromone response. Some fluctua-
tion remained (especially at times immediately after re-
lease from cdc15 arrest), which could represent a minor
effect of cell-cycle position on other targets or a non-
specific effect of the temperature-shift protocol. Overall,
however, it is clear that the Ste5-8A mutant confers a
very strong, if not complete, resistance to G1 CDK regula-
tion of pheromone response.
To discover which of these eight Ste5 sites governs
CDK regulation, we replaced individual Ser or Thr sites
with Ala residues. Remarkably, none of the eight single
(1A) mutants displayed the complete Cln2 resistance
that was shown by Ste5-8A, and instead most conferred
weak partial resistance (Figure 2E) with some variation in
strength. By making combined mutants, we observedCell 128, 519–531, February 9, 2007 ª2007 Elsevier Inc. 521
Figure 2. Multiple CDK Sites Flanking the Ste5 PM Domain Control Cln2/CDK Inhibition
(A) Locations of potential CDK phosphorylation sites (SP or TP) in Ste5 are shown.
(B) Elimination of eight N-terminal CDK sites in Ste5 (Ste5-8A) causes resistance to Cln2. Response to a factor was measured in ste5D ± PGAL1-CLN2
cells expressing Ste5 variants (WT or 8A) from the native STE5 promoter or in ste20D ± PGAL1-CLN2 cells expressing Ste20 variants (WT or 13A) from
the native STE20 promoter. Bars show mean ± SD (n = 8).
(C) CDK resistance caused by 8A mutations restores membrane signaling independent of Ste5-Gbg interaction. Gbg-independent signaling was
activated by PGAL1-STE5-Q59L ± 8A in ste4D ste5D cells ± PGAL1-CLN2. Bars show mean ± SD (n = 7).
(D) The Ste5-8A mutant disrupts cell-cycle periodicity of pheromone response. Cells (cdc15-2 or cdc15-2 STE5-8A) were synchronized in late M
phase by arrest at 36C and then transferred to 25C. At various times, response to brief treatment with a factor was monitored (see Experimental
Procedures). Top panel shows FUS1-lacZ induction (mean of four trials). Bottom panel shows Fus3 activation (phospho-Fus3), which was measured
using phospho-specific antibodies (mean of six trials). Arrows mark the times of bud emergence (see Figures S1D and 5G).
(E) Ste5 phosphorylation sites were replaced with Ala residues either singly (1A) or in various combinations (2A, 3A, 4A, or 8A). Response to a factor
was tested in ste5D strains ± PGAL1-CLN2 (mean + SD, n = 8–16).gradually increasing resistance to Cln2 asmore sites were
removed (Figure 2E), yet complete resistance was seen
only when all eight sites were eliminated. Conversely,
however, while Cln2 could inhibit signaling to a measur-
able degree when Ste5 retained four or five CDK sites, in-
hibition wasmuch stronger when Ste5 retained six, seven,
or eight CDK sites. Clearly, then, no single site controls
sensitivity to Cln2. Rather, multiple CDK sites are required
to fully inhibit Ste5 signaling.
Inhibition Is Proportional to Added Negative Charge
We hypothesized that the addition of anionic phosphates
next to the basic-rich PM domain would interfere with its
electrostatic attraction to acidic phospholipid mem-
branes. Although our findings had hinted that full interfer-
ence might require phosphorylation at multiple Ste5 sites,
it was equally possible that multiple sites merely serve to
increase the likelihood of phosphorylation at one or a
few sites. To address these issues, we replaced the
same Ser/Thr residues with negatively charged Glu resi-
dues (Figure 3A). Placement of Glu residues at all eight
sites (Ste5-8E) did reduce pheromone response but not522 Cell 128, 519–531, February 9, 2007 ª2007 Elsevier Inc.as strongly as it was reduced when Ste5-WTwas inhibited
by Cln2 (Figure 3B). To explain this partial effect, we rea-
soned that if electrostatic interference was the operative
mechanism, then the net charge might dictate the level
of inhibition. Because Ser/Thr phosphorylation introduces
a charge of 2, phosphorylation at eight sites would add
a net charge of 16, whereas eight Glu residues would
add a net charge of only 8 and thus would be less inhib-
itory. To test this notion, we sought to better mimic the2
charge of each phosphate by using two Glu residues, and
sowe replaced the SPor TPdipeptides at each of the eight
Ste5 sites with EE dipeptides (Figure 3A). Indeed, phero-
mone response by this ‘‘Ste5-16E’’ mutant was reduced
to a level similar to that seen when Ste5-WT was inhibited
by Cln2 (Figure 3B). This strong effect required EE dipep-
tides at all eight sites because EE dipeptides at only four
sites either before or after the PM domain (Ste5-up8E or
Ste5-dn8E) caused only a partial reduction, which was
reminiscent of when the eight Glu residues were distrib-
uted among all eight sites (Ste5-8E) except that signaling
could be further inhibited by Cln2 via the remaining four
CDK sites. Several observations suggest that the strong
Figure 3. Strong Inhibition of Ste5 Signaling Requires a Large Number of Negative Charges
(A) Glu-replacement mutations at CDK sites. S/T residues were replaced with E or A, and SP/TP dipeptides were replaced with EE or AA as indicated.
(B) Inhibition of Ste5 signaling is proportional to added negative charge. Ste5 mutants were tested for a factor response in ste5D cells ± PGAL1-CLN2.
Ste5 ‘‘up4A’’ and ‘‘dn4A’’ refer to Ala mutations at sites 1–4 and 5–8, respectively. Bars indicate FUS1-lacZ levels relative to Ste5-WT (mean ± SD,
n = 6).
(C) An anti-myc blot showing levels of Ste5-myc13 mutants expressed in ste5D cells is shown.
(D) The Ste5-16E mutant can still bind Ste4. Extracts of ste4D ste5D cells coexpressing Ste5-myc and GFP-Ste4 (after 3 hr induction of PGAL1-GFP-
STE4) were analyzed by immunoprecipitation (IP) and immunoblotting (blot) as indicated. Ste5-C180A served as a control that is defective at binding
Ste4 (Feng et al., 1998).
(E) Ste5Glumutants are competent tomediate basal signaling (i.e., no a factor) activated by Ste11-4 in ste4D ste5D ste20D cells. Bars indicatemean±
SD (n = 4).
(F) The 16E mutations only inhibit signaling that requires the Ste5 PM domain. FUS1-lacZ (mean ± SD, n = 3–6) was induced in ste4D ste5D cells
(without a factor) by PGAL1-driven expression of Ste5, Ste5-Q59L, or Ste5-CTM, each of which either did contain the 16E mutations (+16E) or did
not contain the 16E mutations (16E). Anti-GFP blots confirmed that protein levels were unaffected by the 16E mutations (data not shown).
(G) Glu mutants disrupt Gbg-independent, membrane-localized signaling. Signaling (mean ± SD, n = 6) was activated in ste4D ste5D cells (without
a factor) by coexpression of PGAL1-STE11-Cpr with the indicated Ste5 derivatives.
(H) Ste5 derivatives containing various Ala or Glu mutations were coexpressed in ste4D ste5D cells with either Ste4-WT or Ste4 mutants (K55E or
N157H S175P) that weaken Ste5 binding (Leeuw et al., 1998; Winters et al., 2005). Response to a factor was measured (mean ± SD, n=6).signaling deficit of the Ste5-16E mutant reflects a specific
effect on the Ste5 PMdomain and not a complete inactiva-
tion of Ste5. First, the Ste5-16E mutant showed normal
protein levels (Figure 3C), and it still bound Ste4 (Gb;
Figure 3D). Second, the Ste5-16E mutant could still medi-
ate basal signaling from an activated Ste11 derivative,
Ste11-4 (Figure 3E), which does not require the Ste5 PM
domain (Mahanty et al., 1999; Winters et al., 2005). Third,
aswith inhibition by Cln2 (see Figure 1C), the 16Emutation
inhibited Ste5-Q59L but not Ste5-CTM (Figure 3F) and
therefore only blocks membrane signaling that requires
the Ste5 PM domain. A control mutant with AA dipeptides
at all eight sites was not informative because it was poorly
expressed and completely defective in all assays. We
traced this to the fact that an AA dipeptide was not toler-
ated at site three or four (data not shown). By allowing sitesthree and four to harbor only single replacements (either A
or E) and by replacing the six other sites with AA or EE di-
peptides, which generated ‘‘Ste5-14A’’ and ‘‘Ste5-14E,’’
we found that Ste5-14A remained functional (and fully re-
sistant to Cln2), whereas Ste5-14E was strongly inhibited
(Figure 3B). Therefore, the EE phenotypes reflect the addi-
tion of charge rather than the multiplicity of mutations. As
with inhibition by Cln2, the Glu replacements affected
membrane-based signaling in general rather than Gbg-
triggered signaling in particular because they also disrup-
ted Gbg-independent signaling by Ste11-Cpr (Figure 3G).
Again, the degree of inhibition was proportional to the
added negative charge. Notably, Ste5-14E retained
more function than Ste5-16E did, which suggests that 16
negative charges are more inhibitory than 14 negative
charges are. This agrees with our finding that removingCell 128, 519–531, February 9, 2007 ª2007 Elsevier Inc. 523
single CDK sites confers partial Cln2 resistance. Because
the Ste5 PM domain normally acts cooperatively with
Ste5-Gbg binding (Winters et al., 2005), we predicted
that the inhibitory effect of a small number of negative
charges would be enhanced when Ste5-Gbg affinity is
reduced. Indeed, when using Ste4 (Gb) mutants with
reduced binding to Ste5, we could now detect inhibition
by one to four added Glu residues (Figure 3H). Thus,
a small number of charges have measurable inhibitory po-
tential, but multiple charges are necessary when the inter-
actions governing Ste5 membrane recruitment occur with
normal affinity. Collectively, the Glu-replacement pheno-
types show that added negative charges disrupt mem-
brane signaling that is mediated by the Ste5 PM domain
and that the requirement for multiple CDK sites truly
reflects a need for adding multiple phosphates.
G1 CDK Activity Disrupts Ste5 Membrane
Localization
Using a Ste5-GFP33 fusion expressed at native levels
(Winters et al., 2005), we found that PGAL1-CLN2 inhibited
pheromone-induced membrane recruitment of Ste5-WT
but not Ste5-8A (Figure S2A). We also used the hyperac-
tive Ste5 variant Ste5-Q59L (Winters et al., 2005) in order
to examine membrane localization that is mediated spe-
cifically by the Ste5 PM domain but which is independent
of upstream factors (e.g., pheromone and Gbg) or down-
stream signaling consequences (e.g., transcriptional
induction and cell-cycle arrest). Expression of Cln2 dis-
placedSte5-Q59L from the plasmamembrane (Figure 4A),
and this effect was blocked by the 8A mutations (Ste5-
Q59L+8A). Results were similar in strains lacking Ste20
or lacking the MAPKs Fus3 and Kss1 (Figure S2), which
rules out any contribution fromCln2/CDK phosphorylation
of Ste20 (Oehlen and Cross, 1998; Wu et al., 1998) or
MAPK phosphorylation of Ste5 (Kranz et al., 1994; Flotho
et al., 2004; Bhattacharyya et al., 2006). Because these
experiments were performed in nonsignaling strains, the
effect of Cln2 was not due to a shift fromG1-arrested cells
to cycling cells. Thus, Cln2/CDK actively inhibits Ste5
membrane localization mediated by the PM domain. To
address whether these localization effects were due to
added negative charge, we examined the Glu-replace-
ment mutations. In agreement with its signaling pheno-
types (see Figure 3F), the 16E mutation disrupted Ste5-
Q59L membrane localization, which depends on the PM
domain, but did not disrupt membrane localization of
Ste5-CTM, which is independent of the PM domain
(Figure 4B). Furthermore, displacement of Ste5 can be as-
cribed to a local effect on the PMdomain (rather thanmore
global changes in Ste5) because Glu mutations blocked
membrane localization of N-terminal Ste5 fragments (Fig-
ure 4C). When membrane binding by an N-terminal frag-
ment was enhanced using the Q59L mutation (Figure 4C,
bottom), displacing it required greater negative charge
(i.e., 16E rather than 8E), which suggests that competition
between attractive and repulsive interactions determines
the net membrane affinity. Collectively, these results524 Cell 128, 519–531, February 9, 2007 ª2007 Elsevier Inc.indicate that phosphorylation near the Ste5 PM domain
disrupts plasma membrane binding.
Cln2-Dependent Phosphorylation of Ste5
To test if Cln2/CDK directly phosphorylates Ste5, we
performed in vitro kinase assays. As a substrate we
Figure 4. Disruption of Ste5 Membrane Localization by G1
CDK Activity or Negative Charge
(A) Localization of GFP-Ste5-Q59L ± 8A, expressed from the GAL1
promoter in ste4D ste7D cells ± PGAL1-CLN2. Note that hyperpolarized
bud growth is due to Cln2 overexpression and not to mating signaling.
Also see Figure S2B.
(B) The 16E mutations disrupt Ste5 membrane localization that is me-
diated by the PM domain (Q59L) but not Ste5 membrane localization
that is mediated by a foreign transmembrane domain (CTM). At top,
membrane localization induces mating-pathway signaling, which
causes pear-shaped ‘‘shmoo’’ morphology. At bottom, localization re-
sults were similar in a nonsignaling strain (ste4D ste7D).
(C) Negative charge disrupts membrane localization of Ste5 N-terminal
fragments. Localization was compared (in ste4D ste7D cells) for WT
and mutant derivatives of GFP-Ste5(1–214) and GST-GFP-Ste5(1–
125), which can localize to the membrane in the absence of phero-
mone, Gbg, and other Ste5 sequences (Winters et al., 2005).
Figure 5. Phosphorylation of Ste5 by Cln2/CDK
(A) Phosphorylation of the Ste5 N terminus by Cln2/Cdc28 in vitro is shown. Bacterially expressed GST-Ste51-125 fusions (WT, 8A, and 8E) were phos-
phorylated by recombinant Cln2/Cdc28. Histone H1 served as a control substrate.
(B) Cln2 expression in vivo alters Ste5 electrophoretic mobility. HA-tagged Ste5 (WT, 8A, and 16E) was immunoprecipitated from the indicated strains
after 3 hr galactose induction (to express Cln2), resolved by SDS-PAGE, and analyzed by anti-HA immunoblot.
(C) The Ste5 mobility shift is due to phosphorylation. Ste5-HA3 was immunoprecipitated from ste5D ± PGAL1-CLN2 strains and treated with calf in-
testinal phosphatase (CIP).
(D) Effects on Ste5 mobility are specific to Cln2. Ste5-HA3 derivatives (WT, 8A, DNLS, and DNLS+8A) were analyzed as in (B) using various PGAL1-
cyclin strains.
(E) Ste5DNLS is more fully modified by Cln2. Ste5-HA3 derivatives were analyzed as in (B).
(F) Ste5DNLS modification is elevated after Start and requires Cln1 and Cln2. WT and mutant strains (‘‘cln1,2’’ = cln1 cln2) expressing Ste5-HA3 (DNLS
or DNLS+8A) were incubated for 3 hr at 37C.
(G)Modification of the Ste5 N terminus is cell-cycle dependent. Cells (cdc15-2 or cdc28-13) harboring Ste5-HA3 (DNLS orDNLS+8A) were arrested at
37C for 3 hr then transferred to 25C to resume cycling. Samples were collected at 20min intervals (0–180min). As cdc15 cells arrest with large buds,
emergence of small buds was used to follow cell-cycle progression (cf. Figure S1D).
In (B)–(G), Ste5-HA3 derivatives were expressed from the native STE5 promoter.used a purified Ste5 fragment (residues 1–125) that
encompasses the PM domain and all eight N-terminal
CDK sites. Purified Cln2/Cdc28 phosphorylated the WT
Ste5 fragment, and this was severely reduced by the 8A
or 8E mutations (Figure 5A). Thus, the N terminus of
Ste5 can serve as a direct Cln2/CDK substrate, and the
CDK sites are required for phosphorylation. In vivo, Cln2
overexpression promoted Ste5 phosphorylation as evi-
denced by reduced electrophoretic mobility (Figure 5B)
that was reversed by subsequent phosphatase treatment
(Figure 5C). This agrees with a previous report that the
phosphorylation status of Ste5 in vivo depends on
Cdc28 (Flotho et al., 2004). The Ste5 mobility shift was
consistent with multiply phosphorylated forms, as it was
comparable to the Ste5-16E mutant, which mimics phos-phorylation at all eight N-terminal sites (Figure 5B). Fur-
thermore, the effect of Cln2 on Ste5 mobility required
the N-terminal CDK sites because Ste5-8A and Ste5-
16E were unaltered by Cln2 (Figure 5B). Results were
similar in strains lacking Fus3 and Kss1 (Figure 5B, bot-
tom), which rules out any contribution from Ste5-affiliated
MAPKs (which can also phosphorylate SP/TP motifs).
Unlike Cln2, overexpression of other cyclins (i.e., Cln3,
Clb5, or Clb2) did not alter Ste5 mobility (Figure 5D), which
agrees with their inability to inhibit pheromone signaling
(Oehlen and Cross, 1994; Oehlen et al., 1998). Thus,
Ste5 is a specific substrate of Cln2/CDK activity in vivo,
and the relevant phosphorylation sites correspond to
those that allow Cln2 to regulate Ste5 signaling. Next,
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Ste5 phosphorylation, but our efforts were hindered by the
low fraction of Ste5 that showed a clear mobility shift.
While a technical issue could be partly to blame (e.g.,
phosphatase activity in cell lysates), we wondered if
Ste5 molecules in different subcellular locales might be
modified to different extents. Indeed, when Ste5 was re-
stricted to the cytoplasm by using the ‘‘DNLS’’ allele
(Winters et al., 2005), Cln2 expression could modify nearly
all Ste5 molecules (Figures 5D and 5E). Phosphorylation
of Ste5DNLS resembled that of WT Ste5 in other respects,
including a specific requirement for Cln2 and for the
eight N-terminal CDK sites (Figures 5D and 5E). By ex-
ploiting these favorable detection properties, we saw
that Ste5DNLS phosphorylation was elevated in cells ar-
rested immediately after Start (cdc4, cdc53, or cdc34)
but not when Cln1 and Cln2 were absent (cdc34 cln1
cln2) nor in cells arrested in G1 (cdc28-4 or cdc28-13;
Figure 5F). Furthermore, in synchronous cultures, phos-
phorylation of Ste5DNLS fluctuated during the cell cycle,
peaking at the onset of budding (Figure 5G). Thus, modifi-
cation of the N-terminal CDK sites in Ste5 occurs as
cells pass Start.
CDK-Resistant Signaling Causes Aberrant
Cell-Cycle Arrest
To understand why it is beneficial to inhibit pheromone
signaling as cells pass Start, we explored the physiologi-
cal consequences of CDK-resistant Ste5 mutants. First,
we examined the G1 specificity of pheromone arrest.
Unlike WT cells, which arrested uniformly in G1, a signifi-
cant fraction of STE5-8A cells (15%) arrested at
a post-Start stage with 2N DNA content (Figure 6A). The
Ste5-8A phenotype was dominant to the WT, and an in-
creasing fraction of 2N arrest was observed as more
CDK sites were removed from Ste5 (Figure 6B), which
suggests that it reflects ectopic (i.e. not G1) signaling
by CDK-resistant Ste5 (rather than a leaky G1 arrest). In-
deed, the post-Start arrest phenotype required the
STE5-8A cells to be cycling at the time of pheromone
addition and was not observed when pheromone was
added to a uniform population of G1 cells (Figures 6C
and S3). Also, pheromone treatment of cycling STE5-8A
cells induced a unique morphology in which mating
projections appeared to emanate from cell buds (Figures
6C and S4), which suggests that signaling responses
occurred during the budding phase of the cell cycle. Re-
markably, elimination of only one or two CDK sites in
Ste5 caused a measurable increase in 2N arrest (Fig-
ure 6B), which shows that full inhibition of Ste5 via multiple
CDK sites serves a physiologically important function.
Accordingly, a substantial level of 2N arrest was also
seen when cells expressed Ste5-8E, which mimics a
form with four added phosphates but which cannot
be inhibited further by Cln2/CDK. We conclude that a
failure of G1 CDKs to downregulate the mating MAPK
pathway is detrimental, as it allows pheromone to arrest
cells at an inappropriate cell-cycle stage. Because
STE5-8A cells can arrest at either G1 or post-Start stages,526 Cell 128, 519–531, February 9, 2007 ª2007 Elsevier Inc.the percentage that arrest at the latter stage (usually
15% 2N) likely reflects the fraction of cells in the asyn-
chronous culture that were between the two arrest
points. Indeed, when pheromone was added to STE5-
8A cultures at different times after leaving G1, the level
of 2N arrest roughly correlated with the fraction of the
initial cell population that was in S phase (Figure S3).
Hence, cells outside this susceptible window likely
arrest in G1. Consistent with this view, the majority of
STE5-8A cells could be trapped at the 2N stage when
G1 arrest mechanisms were bypassed. Specifically, over-
expression of the B-type cyclin Clb5 can push cells
through Start even in the presence of pheromone, thereby
makingWT cells pheromone resistant (Oehlen et al., 1998,
and references therein). In STE5-8A cells, however, Clb5
overexpression could still push cells through Start,
but the cells arrested in response to pheromone and did
so almost entirely at the 2N stage (Figure 6D). There-
fore, signaling by CDK-resistant Ste5 has a dangerous
potential to disrupt events during a post-Start window
of the cell cycle.
CDK-Resistant Ste5 Permits
Far1-Independent Arrest
To further explore the consequences of CDK-resistant
signaling, we tested the role of Far1, which is ordinarily re-
quired for pheromone-induced arrest (Chang and Hersko-
witz, 1990). Strikingly, the CDK-resistant Ste5-8A mutant
restored pheromone arrest to far1D cells (Figure 6E). Re-
moval of as few as one or two CDK sites in Ste5 allowed
significant suppression of the far1D arrest defect, and
removing more sites caused even stronger suppression
(Figures 6F and S5A). Thus, Far1 becomes dispensable
when Ste5 signaling cannot be inhibited. Indeed, far1D
cells could be arrested (Figure 6G) by activating the mat-
ing pathway with CDK-resistant constructs (PGAL1-STE5-
Q59L+8A, PGAL1-STE5-CTM) but not with CDK-sensitive
constructs (PGAL1-STE4, PGAL1-STE5-Q59L). Far1-inde-
pendent arrest has been observed in previous studies
but remains poorly understood (Chang and Herskowitz,
1990; Valdivieso et al., 1993; Tyers, 1996; Oehlen et al.,
1998; Cherkasova et al., 1999). Our results indicate that
pheromone signaling is capable of robust growth arrest
without Far1, but this is masked in far1D cells because
the absence of Far1 allows Cln/CDK to downregulate
Ste5.
Pheromone signaling in far1D STE5-8A cells caused ar-
rest at more than one stage because treated cultures
showed a heterogeneous mix of 1N and 2N cells (Figures
6H and S5B) as well as unbudded and budded cells (data
not shown) despite an immediate cessation of prolifera-
tion (Figure S5C). TheG1 arrest appeared somewhat leaky
and could be counteracted by G1 CDK activity (Fig-
ure S5B). Most notably, Far1 proved entirely dispensable
for the post-Start arrest because the near-uniform 2N ar-
rest seen inSTE5-8A cells overexpressingClb5 (Figure 6D)
was independent of Far1 (Figure 6H). Altogether, our re-
sults indicate that CDK-resistant signaling by Ste5-8A
Figure 6. CDK-Resistant Ste5 Allows Aberrant Arrest
(A) Pheromone arrests someSTE5-8A cells at a post-Start (2N) stage. Cells were treatedwith a factor for the indicated times. FACSprofiles showDNA
content.
(B) The post-Start arrest phenotype is dominant and reflects the level of CDK resistance of Ste5. WT cells harboring STE5 plasmids (1A#5 = site 5;
1A#1 = site 1; 2A = sites 5–6) were treated with a factor for 3.25 hr. The percent of cells with 2N DNA content was quantified by FACS (mean ±
SD; n = 4). The dashed line marks the percent 2N value observed when the STE5-WT plasmid is present in WT cells.
(C) G1 phase STE5-8A cells were purified by centrifugal elutriation and treated with a factor either immediately or after cells resumed cycling.
Arrest phenotypes were then compared. See Figures S3 and S4 for the complete data set. Arrowheads show cell buds with a factor-induced
projections.
(D) STE5-8A allows near-uniform 2N arrest when G1 arrest is bypassed using PGPD1-CLB5. The left panel shows DNA content of cells after 3 hr ±
a factor. The right panel shows halo assays of growth arrest by a factor.
(E) Halo assays demonstrating that STE5-8A restores pheromone arrest to far1D cells are shown.
(F) Suppression of the far1D arrest defect increases as more CDK sites are eliminated from Ste5. Five-fold serial dilutions of strains harboring STE5
plasmids (1A = site 5; 2A = sites 5–6; 4A = sites 1–4) were incubated on Ura plates ± 1 mM a factor.
(G) Pathway activation by CDK-resistant constructs causes Far1-independent arrest. Deletion strains harboring PGAL1-regulated activators of the
mating pathway were grown on Ura glucose or galactose plates.
(H) The post-Start arrest triggered by Ste5-8A signaling is independent of Far1. The indicated strains were analyzed in parallel with those in (D).can impede cell-cycle progression of both G1 and post-
Start cells in a Far1-independent manner. Therefore,
cell-cycle control of Far1 (McKinney et al., 1993; Henchoz
et al., 1997) is not sufficient for cells to escape the arrest
effects of pheromone, and instead downregulation of
Ste5 is also critical.DISCUSSION
Mechanism for Cell-Cycle Regulation of MAP Kinase
Cascade Signaling
In this study we define a mechanism by which G1 CDKs
inhibit signaling through the yeast mating MAPK cascade.Cell 128, 519–531, February 9, 2007 ª2007 Elsevier Inc. 527
Figure 7. Model for G1 CDK Inhibition of Ste5 Signaling
(A) As cells pass Start, G1 CDK activity inhibits pheromone signaling by phosphorylating CDK sites that flank the PM domain in Ste5. The negatively
charged phosphates interfere with binding between the basic PM domain and the anionic phospholipid membrane.
(B) Ste5 serves as an integration point for both external and internal regulatory cues, which act through the Gbg-binding domain and the membrane-
binding domain.
(C) Far1 promotes pheromone arrest by inhibiting Cln/CDK activity, but Far1-independent arrest pathways also exist and are revealed when Ste5
signaling cannot be downregulated by Cln/CDK activity.We show that the MAPK cascade scaffold protein Ste5 is
the target of this inhibition and that G1CDK activity inhibits
signaling by phosphorylating sites that flank a membrane-
binding domain in Ste5. Our findings support a model in
which these negatively charged phosphates disrupt Ste5
membrane association by electrostatic interference (Fig-
ure 7A). Hence, through the use of two weak interactions
that cooperatively control its membrane recruitment,
Ste5 serves as an integration point for both external and
internal regulatory cues (Figure 7B) in a way such that sig-
naling is activated only when two conditions are satisfied
(i.e., when pheromone is present and the cell-cycle stage
is appropriate). The physiological benefit of this arrange-
ment is that it restricts pheromone arrest to G1, thus pre-
venting inappropriate disruption of cell-cycle progression
in cells that have passed Start.
The regulatory CDK sites in Ste5 lie in sequences flank-
ing the PM domain that are dispensable for its normal sig-
naling role (Winters et al., 2005; see also Figure S1B) and
that are predicted to be mostly random coil (Figure S6).
Hence, rather than affecting a specific tertiary structure,
the phosphorylated N terminus of Ste5 may behave as
an unstructured electronegative mass, thereby making
juxtaposition to its target energetically unfavorable. This
mode of regulation may be generally applicable where
phosphorylation serves to disrupt interactions. Phosphor-
ylation of Ste5 provides a variation on ‘‘electrostatic
switch’’ mechanisms seen in other signaling proteins
such as Src or MARCKS, in which membrane interactions
are disrupted by phosphorylation within a membrane-
binding domain (McLaughlin and Aderem, 1995). In Ste5,
the use of sites distal to the membrane-binding domain
may impose a requirement for adding multiple phos-
phates, which is likely to be advantageous to the regula-
tory circuit (see below).528 Cell 128, 519–531, February 9, 2007 ª2007 Elsevier Inc.Multisite Phosphorylation as a Sensor
for High CDK Activity
Inhibition of Ste5 signaling requires phosphorylation at
multiple CDK sites, and maximal inhibition of Ste5 is re-
quired to avoid aberrant arrest. This behavior suggests
that multisite phosphorylation of Ste5 serves as a sensor
for high G1 CDK activity, so that signaling is not fully in-
hibited until CDK activity is high enough to promote cell-
cycle entry. Conceptually, this tactic is similar to that
used by the B-type cyclin/CDK-inhibitor protein Sic1,
which must be phosphorylated on at least six CDK sites
to trigger its degradation and the resultant progression
into S and M phases (Nash et al., 2001). In each example,
multisite phosphorylation likely enables a sharp pheno-
typic switch between distinct cell-cycle stages. Unlike
Sic1, we saw no indication that CDK phosphorylation (or
added Glu residues) affects Ste5 protein stability. More-
over, the effects of CDK on Ste5 may be rapidly reversible
because chemical inactivation of Cdc28 can immediately
restore pheromone response to post-Start cells (Colman-
Lerner et al., 2005). Thus, robust dephosphorylation by
cellular phosphatases may also help enforce a demand
for high G1 CDK levels to inactivate Ste5 signaling.
Cell-Cycle Arrest by Pheromone
Cell-cycle control of Ste5 signaling is necessary to avoid
an aberrant pheromone arrest. The best-known mediator
of pheromone arrest is the CDK-inhibitor Far1, yet for
years it has been evident that Far1-independent arrest
pathways must exist because Far1 is dispensible in cells
that lack Cln2 (Chang and Herskowitz, 1990) or all three
G1 cyclins (Tyers, 1996; Oehlen et al., 1998). Our results
show that MAPK signaling can arrest growth without
Far1, but this is ordinarily masked in far1D cells because
Ste5 gets inactivated by G1 CDKs (Figure 7C). Hence,
when Ste5 cannot be inhibited, the Far1-independent
arrest is revealed. This can explain the preferential ability
of cln2D to suppress far1D (Chang and Herskowitz,
1990) because, of the three G1 cyclins, Cln2 is the stron-
gest at inhibiting pheromone response (Oehlen and Cross,
1994). Therefore, although cells eliminate Far1 as they
pass Start (McKinney et al., 1993; Henchoz et al., 1997),
this regulation is essentially futile without also down-
regulating Ste5 signaling.
The mechanisms by which CDK-resistant Ste5 signal-
ing can impede cell-cycle progression are largely
unknown. The ability of Ste5-8A to trigger a G1 arrest (or
delay) without Far1 is consistent with reports that phero-
mone can repress G1/S transcription (Valdivieso et al.,
1993; Cherkasova et al., 1999). This repression may nor-
mally act in conjunction with Far1 to promote a robust,
stable G1 arrest, yet it may still allow a weak G1 arrest in
far1D cells. The post-Start arrest is more enigmatic. A sim-
ilar phenotypewas seen in cells lackingG1 cyclins (Oehlen
et al., 1998) or expressing a stable form of Far1 (McKinney
and Cross, 1995). In light of our findings, these prior cases
may result from disrupted Cln/CDK regulation of Ste5. The
window of susceptibility to post-Start arrest roughly over-
laps S phase, which is consistent with the period in which
pheromone signaling is normally downregulated (Oehlen
and Cross, 1994), and preliminary work suggests that
the 2N cells cannot enter mitosis (S.C.S. and P.M.P., un-
published data), but the molecular cause remains
unknown. Possibly, signaling events that ordinarily help
promote G1 arrest (e.g., CDK inhibition and transcriptional
repression) can also block later cell-cycle steps if signal-
ing is unabated. Or, MAPK signaling during S phase might
induce DNA damage or replication errors, thus triggering
a checkpoint arrest. Alternatively, physiological changes
induced by the mating pathway (e.g., cytoskeletal re-
arrangements) may clash with cell division due to bio-
chemical incompatibility or competition. In any scenario,
downregulation of Ste5 would allow cells to properly com-
mit to a new division cycle by eliminating impediments to
cell-cycle progression.
Coordinating Signaling with Cell-Cycle Stage
The discovery that cells sharply alter their sensitivity to ex-
trinsic stimuli upon commitment to division played an im-
portant role in the formulation of early models for the cell
cycle (Hartwell et al., 1974). Sharp transitions between
distinct cell-cycle stages can be ensured by feedback
loops (Brandman et al., 2005). In the pheromone response
pathway, mutual reinforcement between Ste5 and Far1 (in
which Ste5-dependent signaling activates Far1 and Far1
blocks inactivation of Ste5) establishes a positive feed-
back loop. Conversely, Cln/CDK inhibition of both proteins
can facilitate a decisive switch between conflicting states
(i.e., arrest versus proliferation).
During animal development, control of cell fate by exter-
nal signals often occurs in the context of carefully orches-
trated patterns of cell division (Vidwans and Su, 2001).
Thus, it may be generally important to coordinate the re-sponse to differentiation signals with cell-division status.
While it is common for MAPK cascades to regulate the
cell cycle, the reciprocal regulation is less well appreci-
ated, yet its utility is clearly demonstrated by the behavior
of the pheromone response pathway. Such mutual antag-
onism can also occur in pathways that do not involve
MAPKs, as in the TGFb pathway, where antiproliferative
signaling by Smad3 is inhibited by G1 CDKs (Matsuura
et al., 2004). Thus, while themechanismsmay vary, we ex-
pect that the beneficial role of coordinating signaling with
cell-cycle stage will be shared by other antiproliferative
pathways.
EXPERIMENTAL PROCEDURES
Strains and Plasmids
Yeast strains are listed in Table S1. Information on strain construction
can be found in the Supplemental Experimental Procedures. Plasmids
are listed in Table S2.
Signaling Assays
FUS1-lacZ induction and b-galactosidase assays were performed as
described (Pryciak and Huntress, 1998; Lamson et al., 2002). Activa-
tion of FUS1-lacZ by galactose-inducible constructs in the presence
and absence of PGAL1-CLN2 was measured 3 hr after addition of 2%
galactose to cultures grown in 2% raffinosemedia. Tomeasure effects
of PGAL1-CLN2 on FUS1-lacZ induction by pheromone, cells were
grown in 2% raffinose media then induced with 2% galactose for
1 hr, followed by induction with 5 mM a factor for an additional 2 hr.
For FUS1-lacZ experiments not involving PGAL1-CLN2, cells grown in
glucose media were treated with 5 mM a factor for 2 hr.
For signaling in synchronous cultures, cdc15 strains AA2596 and
PPY1761 harbored either pPP1044 (FUS1-lacZ) or pPP1513 (Fus3-
myc13). Cultures in selective media were diluted into YPD and grown
overnight at 25C, shifted to 36C for 3 hr, then pelleted and resus-
pended in YPD at 25C to release the mitotic block. To measure
FUS1-lacZ induction, aliquotswere harvested every 15min and treated
with 10 mM a factor for 22min. Induction was stopped by transfer to an
ice-water bath. Tomeasure Fus3 activation, every 30min aliquots were
treated with 5 mM a factor for 8 min. Cells were then pelleted, frozen in
dry ice, andstoredat80C.Fus3-myc13was immunoprecipitated from
cell extracts, and phospho-Fus3was detected by rabbit anti-phospho-
p44/42 blots (#9101; Cell Signaling Technology), quantified by densi-
tometry, normalized to Fus3-myc13 levels measured in separate anti-
myc blots, and expressed relative to time 0 for each experiment.
Halo assays (Lamson et al., 2002) used 20 ml of 1mM (Figures 6E and
S5A), 200 mM (Figure S5A), 100 mM (Figures 6D, 6H, S1C, and S5B), or
20 mM (Figure S1C) a factor. Unless indicated otherwise, growth arrest
was monitored after incubation for 2 days at 30C.
FACS Analysis
For FACS experiments, bar1D strains were treated with 1 mM a factor
in order to minimize the possibility of leaky arrest. Results were similar
using 0.1 mM a factor (data not shown). Cells were grown to OD660 =
0.2–0.3 in YPD and incubated ± a factor at 30C. For experiments
involving plasmids, cells grown overnight in selective media were
transferred to YPD for 1.5 hr prior to a factor addition. Cells were
analyzed by FACS as described (Haase and Reed, 2002); instead of
pepsin, cells were treated with 0.2 ml Proteinase K solution (1 mg/ml
in 50 mM Tris, pH 8.0) for 1 hr at 36C.
Immunoblotting
Immunoprecipitation and yeast extract preparation used published
methods (Lamson et al., 2002). Immunoprecipitation of Ste5-myc13,
Fus3-myc13, Ste5-HA3, and GFP-Ste4 used mouse anti-myc (9E10;Cell 128, 519–531, February 9, 2007 ª2007 Elsevier Inc. 529
Santa Cruz Biotech), anti-HA (HA.11; Covance), and anti-GFP (clones
7.1 and 13.1; Roche) antibodies. Blots were probed with rabbit anti-
myc (A-14; Santa Cruz Biotech), rabbit anti-HA (Y-11; Santa Cruz Bio-
tech), ormouse anti-GFP (B34; Covance). Analysis of phosphorylation-
dependent mobility of Ste5-HA3 used a lysis buffer with high salt and
phosphatase inhibitors (Harvey et al., 2005) and 10% polyacrylamide
(30:1 acryl:bis) gels. Phosphatase treatment of Ste5-HA3 was per-
formed as described (Chang and Herskowitz, 1992).
Kinase Assays
GST-Ste51-125 fusions (WT, 8A, and 8E) were purified from E. coli strain
BL21-Codon Plus (Stratagene) using glutathione-Sepharose beads.
The Cln2/Cdc28 complex was purified from Sf9 insect cells infected
with recombinant baculoviruses (Nash et al., 2001). Cln2/Cdc28
(100 ng) was mixed with GST-Ste51-125 (30 mg) or histone H1 (1 mg)
in 10 ml of reaction buffer (50 mM Hepes pH 7.5, 10 mM MgCl2,
1 mM DTT, 10 mCi [32P]-g-ATP, and 100 mM cold ATP) and incubated
for 30 min at 30C. Products were resolved by SDS-PAGE and stained
with Coomassie blue. Gels were then dried and analyzed by auto-
radiography.
Microscopy
GFP fusions to Ste5 (full-length or fragments) were visualized without
fixation and after induction from theGAL1 promoter with 2%galactose
for 2–4 hr (Pryciak and Huntress, 1998; Winters et al., 2005). Results
representative of multiple repeated experiments are shown.
Supplemental Data
Supplemental Data include two tables, six figures, Supplemental
References, and Supplemental Experimental Procedures and can be
found with this article online at http://www.cell.com/cgi/content/full/
128/3/519/DC1/.
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